Coronary Artery Disease (CAD) Protocol

CardiovascularModerate Evidence

supplements

Primary

Supporting

Grade A

Studies

Primary Stack

Core supplements with strongest evidence

Omega-3 Fatty AcidsA

2-4g EPA/DHA daily

Reduces triglycerides, inflammation, platelet aggregation, and arrhythmia risk in established CAD

Atrial Fibrillation Incidence↑Platelet Aggregation↓Blood glucose↓Blood Pressure↓C-Reactive Protein (CRP)

40 studies135,000 participants

Supporting Studies (2)

PMID: 30415628 - REDUCE-IT: Icosapent ethyl reduces CV events in high-risk patients (2019)PMID: 31567797 - Omega-3 fatty acids for cardiovascular disease: Cochrane review (2019)

Coenzyme Q10A

100-300mg daily

Supports mitochondrial ATP production in cardiac muscle and provides antioxidant protection

↑Anti-Oxidant Enzyme Profile↓Oxidative Stress Biomarkers↓Cardiovascular Disease Mortality↑Endogenous Advanced Glycation End Products↑High-density lipoprotein (HDL)

25 studies2,500 participants

Supporting Studies (2)

PMID: 25282031 - Q-SYMBIO: CoQ10 reduces mortality in heart failure (2014)PMID: 28854422 - Coenzyme Q10 and cardiovascular disease: meta-analysis (2017)

Supporting Stack

Additional supplements for enhanced results

MagnesiumB

300-400mg daily

Supports endothelial function, reduces blood pressure, and helps maintain normal heart rhythm

↓C-Reactive Protein (CRP)↓Homocysteine↑Serum Magnesium

22 studies1,200 participants

Supporting Studies (1)

PMID: 28212818 - Magnesium supplementation and cardiovascular risk: meta-analysis (2017)

Vitamin K2B

100-200mcg MK-7 daily

Activates matrix Gla protein, directing calcium away from arteries and reducing vascular calcification

↓Body FatHigh-density lipoprotein (HDL)Cardiovascular Disease Mortality↓Risk Of Cardiovascular Disease↓Oxidative Stress Biomarkers

12 studies800 participants

Supporting Studies (1)

PMID: 25694037 - Vitamin K2 reduces coronary artery calcification progression (2015)

How This Protocol Works

Simple Explanation

Coronary artery disease (CAD) develops when plaque builds up in the arteries supplying the heart, reducing blood flow and increasing heart attack risk. While medications and lifestyle changes are the foundation of treatment, certain supplements can provide additional cardiovascular protection.

•Omega-3 Fatty Acids (fish oil) have multiple heart benefits: they lower triglycerides, reduce inflammation, decrease platelet stickiness, and stabilize heart rhythm. The landmark REDUCE-IT trial showed high-dose EPA (4g/day) reduced cardiovascular events by 25% in high-risk patients. This level of evidence has made prescription omega-3s a standard treatment.

•Coenzyme Q10 is essential for energy production in the heart—the most energy-demanding organ. Statin medications (commonly prescribed for CAD) deplete CoQ10, and supplementation may reduce statin side effects. The Q-SYMBIO trial showed CoQ10 reduced cardiovascular mortality in heart failure patients.

•Magnesium helps blood vessels relax, supports healthy blood pressure, and maintains normal heart rhythm. Deficiency is common and associated with increased cardiovascular risk.

•Vitamin K2 (specifically MK-7) activates proteins that keep calcium in bones and out of arteries. Studies show it can slow the progression of coronary artery calcification.

Expected timeline: Omega-3s lower triglycerides within 2-4 weeks; other benefits develop over months to years. CoQ10 effects may take 4-12 weeks. Magnesium benefits blood pressure within 1-2 months.

Important: These supplements complement, not replace, medications prescribed by your cardiologist.

Clinical Perspective

CAD pathophysiology involves endothelial dysfunction, lipid accumulation, inflammation, and plaque formation/instability. Secondary prevention requires addressing modifiable risk factors. This protocol provides adjunctive support targeting inflammation, energetics, and calcification.

•Omega-3 Fatty Acids (A-grade): EPA and DHA reduce hepatic VLDL synthesis (lowering TG 20-50%), decrease inflammatory eicosanoids, improve endothelial function via NO pathway, and stabilize cardiomyocyte membranes (antiarrhythmic). REDUCE-IT trial (n=8179): 4g icosapent ethyl reduced MACE by 25% (PMID: 30415628). EPA-only formulations may be superior to EPA+DHA. Prescription omega-3s achieve higher doses than OTC.

•Coenzyme Q10 (A-grade): Essential cofactor in mitochondrial electron transport chain (Complex I-III). Cardiac tissue has highest CoQ10 concentration. Statins inhibit HMG-CoA reductase, reducing CoQ10 synthesis. Q-SYMBIO trial: 300mg/day reduced CV mortality 43% in HF patients (PMID: 25282031). Meta-analysis confirms improved ejection fraction and functional capacity (PMID: 28854422). Ubiquinol form has better absorption.

•Magnesium (B-grade): Regulates vascular smooth muscle tone via calcium channel antagonism. Required for Na+/K+-ATPase maintaining cardiac membrane potential. Deficiency increases arrhythmia risk. Meta-analysis: modest BP reduction (PMID: 28212818). Check RBC magnesium (serum insensitive). Target intake 400-420mg/day (men), 310-320mg/day (women).

•Vitamin K2 (MK-7) (B-grade): Activates matrix Gla protein (MGP), the most potent inhibitor of vascular calcification. Warfarin inhibits vitamin K cycle, potentially accelerating calcification. 3-year RCT: MK-7 180mcg/day reduced CAC progression (PMID: 25694037). MK-7 has longer half-life than MK-4.

Biomarker targets: Lipid panel, TG/HDL ratio, hs-CRP, coronary artery calcium score, serum/RBC magnesium.

Protocol notes: CRITICAL: Coordinate with cardiologist. Omega-3s: use Rx-grade for highest doses; may increase bleeding with anticoagulants. CoQ10: monitor INR if on warfarin. Vitamin K2: contraindicated with warfarin unless closely monitored. Consider adding niacin (if not on statin), aged garlic extract, or plant sterols based on lipid profile.

View All Protocols